Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 8/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6807547 | 0.99 | KDR (0.45) | KDRRAB9ANPC1LCKMAPK14 | |
| Hydrochloric Acid SCHEMBL7840046 | 0.93 | KDR (0.41) | KDRRAB9ANPC1LCKMAPK14 | |
| SCHEMBL6801238 | 0.88 | RAB9A (0.51) | RAB9ANPC1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL6805039 | 0.87 | ALDH1A1 (0.38) | KDRRAB9ANPC1LCKMAPK14 | |
| SCHEMBL6806905 | 0.84 | RAB9A (0.47) | KDRRAB9ANPC1LCKMAPK14 | |
| Hydrochloric Acid SCHEMBL6805952 | 0.83 | RAB9A (0.46) | KDRRAB9ANPC1LCKMAPK14 | |
| SCHEMBL6802170 | 0.82 | MAPT (0.42) | RAB9ANPC1LCKMAPK14KMT2A | |
| SCHEMBL6806932 | 0.81 | KMT2A (0.49) | RAB9ANPC1KMT2AKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6810718 | 0.81 | MAPT (0.41) | RAB9ANPC1LCKMAPK14KMT2A | |
| SCHEMBL6810117 | 0.81 | LCK (0.42) | KDRRAB9ALCKMAPK14SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1084122-B1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2003-10-22 | — | — | EP | claimed |
| US-20020143029-A1 | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity | SMITHKLINE BEECHAM P.L.C. | 2002-10-03 | — | — | US | claimed |
| US-6410555-B1 | ANTIEPILEPTIC AGENTS; HEADACHES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-25 | — | — | US | claimed |
| US-6762192-B2 | USEFUL IN THERAPY AND PROPHYLAXIS OF EPILEPSY, MIGRAINE, AND OTHER DISORDERS | SMITHKLINE BEECHUM P.L.C. (GB) | 2004-07-13 | — | — | US | disclosed |
| EP-1084122-B1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2003-10-22 | — | — | EP | disclosed |
| US-20020143029-A1 | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity | SMITHKLINE BEECHAM P.L.C. | 2002-10-03 | — | — | US | disclosed |
| US-6410555-B1 | ANTIEPILEPTIC AGENTS; HEADACHES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-25 | — | — | US | disclosed |
| EP-1084122-A1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999065903-A1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143029-A1 | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity | CNR1, SCN1B, CNR2 | KDR 2764/4885RAB9A 4276/4885NPC1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.